Pacific Therapeutics Ltd., a clinical stage pharmaceutical company that repurposes and reformulates already approved drugs for larger markets such as cystic fibrosis, recently announced that the United States Patent Office (USPO) has issued United States Patent No. 9029385 for its patent application, “Compositions and Methods for Treating Fibroproliferative Disorders.” The issuance of the patent has positive implications for the company’s continued work into treating Idiopathic Pulmonary Fibrosis.
Doug Unwin, the President and CEO, said in a press release: “This is a huge milestone for the Company as it adds additional protection to our already issued patents for the technology in PTL-202 our lead candidate for pulmonary and of the fibrotic diseases.”
PTL-202 is Pacific Therapeutics’ lead drug candidate for addressing fibrosis (which includes progressive scarring of the lungs) and it consists of a combination of Pentoxifylline (an already FDA-approved drug currently used to treat leg cramps) plus an amino acid and a very strong, relevant antioxidant. The positive outcomes from its phase 1 clinical trial, along with the pre-clinical results, will support further advancement of the product to address treatment for diseases such as Idiopathic Pulmonary Fibrosis and Liver Cirrhosis.
In addition to PTL-202’s potential to treat IPF, the company’s main development programs are focused on erectile dysfunction and other diseases related to excessive scarring (fibrosis). The company plans to conduct additional clinical testing on other diseases and conditions for further marketing authorizations. Pacific believes that this strategy can lead to reduction of risk, cost and time in developing therapies, since the risks of basic research and utilization of unknown compounds with unknown safety and toxicity profiles are avoided.